Case Studies in Cardiovascular Disease Prevention and People with HIV (Web)

A. CVD in PWH is exclusively caused by antiretroviral therapies, which can cause metabolic abnormalities.B. CVD in PWH is caused by the increased age of PWH, a population in which one would expect increased CVD.C. CVD in PWH is caused by AIDS-related opportunistic infections of the heart.D. CVD in PWH is caused by a combination of traditional and non-traditional risks, including inflammatory and immune-mediated mechanisms.

Congratulations. The best choice is D, both traditional and nontraditional inflammatory risks contribute to CVD In PWH. The effects of ART on metabolic disorders are thought to contribute only in small part to CVD in PWH. Despite the fact that the PWH population is aging, CVD can, and often does, occur in young PWH who have premature CVD for their age. AIDS-related opportunistic infections are not thought to underlie the increased rates of CVD in PWH.

Sorry, the correct answer is D, both traditional and nontraditional inflammatory risks contribute to CVD In PWH. The effects of ART on metabolic disorders are thought to contribute only in small part to CVD in PWH. Despite the fact that the PWH population is aging, CVD can, and often does, occur in young PWH who have premature CVD for their age. AIDS-related opportunistic infections are not thought to underlie the increased rates of CVD in PWH.

A. Pitavastatin 4 mgB. Atorvastatin 20 mgC. Rosuvastatin 10 mgD. Initiate moderate-intensity statin therapy with any of the above options

Congratulations. The best answer is D, initiate moderate-intensity statin therapy with any of the above options. According to the DHHS guidelines, for individuals with HIV aged 40-75 years with a 10-year ASCVD risk between 5% and, 20%, the recommendation is to initiate moderate-intensity statin therapy.

Sorry, the best answer is D, initiate moderate-intensity statin therapy with any of the above options. According to the DHHS guidelines, for individuals with HIV aged 40-75 years with a 10-year ASCVD risk between 5% and, 20%, the recommendation is to initiate moderate-intensity statin therapy.

A. Initiate low-intensity statin therapyB. Initiate high-intensity statin therapyC. Initiate at least moderate-intensity statin therapyD. Do not initiate statin therapy but instead work with individual on risk behavior modification such as smoking cessation.

Congratulations. The best answer is C. Based on the information provided, the individual is a white female with HIV, age 45 years, reporting current tobacco use and hypertension, having an LDL of 130 mg/dL, and a calculated 10-year ASCVD risk of 2.5%. According to recent clinical guidance and considering the multiple risk factors, initiation of at least moderate-intensity statin therapy is recommended. This approach aims to address the combination of HIV-related factors, age, tobacco use, hypertension, and LDL level, contributing to an overall cardiovascular risk. The emphasis on moderate-intensity statin therapy aligns with the current guidelines for primary prevention in this specific population.

Sorry, the best answer is C. Based on the information provided, the individual is a white female with HIV, age 45 years, reporting current tobacco use and hypertension, having an LDL of 130 mg/dL, and a calculated 10-year ASCVD risk of 2.5%. According to recent clinical guidance and considering the multiple risk factors, initiation of at least moderate-intensity statin therapy is recommended. This approach aims to address the combination of HIV-related factors, age, tobacco use, hypertension, and LDL level, contributing to an overall cardiovascular risk. The emphasis on moderate-intensity statin therapy aligns with the current guidelines for primary prevention in this specific population.

YesNoRemained the same

	Strongly Agree (5)	Agree (4)	Neutral (3)	Disagree (2)	Strongly Disagree (1)
The content covered was useful and relevant to my current or future scope of practice.
The activity was fair, balanced, and free of bias.
The activity improved my knowledge of this clinical issue.
The learning objectives for this activity were achieved.
I am better able to: Communicate/collaborate with other members of the care team on this issue.
I am better able to: Improve access to care and treatment for underrepresented patient groups or geographies because of what I learned.
The information learned during this activity will help improve my skills or judgment within the next six months.
The content was presented clearly.
The educational activity was well planned and presented.

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
I intend to: Modify/change my practice or the practice of my team based on this educational activity.
I intend to: Work with my team to create/revise protocols, policies, and/or procedures with my care team.
I intended to: Share what I learned with other members of my care team.
I intend to: Make changes in how I communicate with/educate my patients.
I intend to: Seek additional information on topics discussed during the activity.
On average, I utilized the patient treatment strategies described in this educational activity prior to my participation.

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
My office and practice systems can accommodate the above changes.
My patients can accommodate the above changes.
Patient access to the treatments provided will be a barrier to implementing the above changes.

	Excellent (5)	Good (4)	Acceptable (3)	Poor (2)	Very Poor (1)
Activity Rating

Please provide the following informaiton to receive your CME/CE Certificate.

Confirmation Emailexample@example.com

The certificate emails auto-generated by this form are blocked by comcast.net email addresses. Please use an alternate email address if possible, or contact CEServices@academycme.org after submitting your form. **

Street Address

Street Address Line 2

State / Province

Country

This educational activity was certified for a maximum of 1.0 AMA PRA Category 1 Credits(TM), 1.0 ANCC Contact Hours, 1.0 AAPA Category 1 CME credits, and 1.0 ACPE Contact Hours.

Case Studies in Cardiovascular Disease Prevention and People with HIV

Assessment

Evaluation